Journal: Aging (Albany NY)

Article Title: The protective effects of Phoenixin-20 in tumor necrosis factor α (TNF-α)-induced cell senescence of rheumatoid arthritis fibroblast-like synoviocytes (FLS)

doi: 10.18632/aging.205024

Figure Lengend Snippet: Phoenixin-20 downregulated p53 and p21 in TNF-α-treated RA-FLSs. RA-FLSs were stimulated with TNF-α (10 ng/mL) with or without Phoenixin-20 (10, 20 nM) for 7 days. ( A ) mRNA of p53 and p21; ( B ) Protein of p53 and p21 ( ※ P < 0.01 vs. vehicle group; # , ## , P < 0.05, 0.01 vs. TNF-α group, N = 5–6).

Article Snippet: The primary antibodies against p53 (#AB_2860544, 1:2000, Sino Biological, China), p21 (1:1000, #ab109520, Abcam, USA), STAT6 (#ab32108, 1:1500, Abcam, USA), and β-actin (1:10000, #ab6276, Abcam, USA) were imported.

Techniques:

Journal: Aging (Albany NY)

Article Title: The protective effects of Phoenixin-20 in tumor necrosis factor α (TNF-α)-induced cell senescence of rheumatoid arthritis fibroblast-like synoviocytes (FLS)

doi: 10.18632/aging.205024

Figure Lengend Snippet: Overexpression of STAT6 abolished the protective effect of Phoenixin-20 on TNF-α-induced cellular senescence in RA-FLSs. Cells were transduced with lentiviral STAT6, followed by stimulation with TNF-α (10 ng/mL) and Phoenixin-20 (20 nM) for 7 days. ( A ) Western blot analysis revealed successful overexpression of STAT6; ( B ) mRNA of p53 and p21. ( C ) Cellular senescence was assayed using SA-β-gal staining ( ※ P < 0.01 vs. vehicle group; ## P < 0.01 vs. TNF-α group, * P < 0.05 vs. PNX-20 group, N = 5–6).

Article Snippet: The primary antibodies against p53 (#AB_2860544, 1:2000, Sino Biological, China), p21 (1:1000, #ab109520, Abcam, USA), STAT6 (#ab32108, 1:1500, Abcam, USA), and β-actin (1:10000, #ab6276, Abcam, USA) were imported.

Techniques: Over Expression, Transduction, Western Blot, Staining

Journal: OncoTargets and Therapy

Article Title: Evaluation of p53 gene expression and prognosis characteristics in uveal melanoma cases

doi: 10.2147/ott.s136785

Figure Lengend Snippet: Figure 1 Expressions of p53 mRNA in (A) MUM-2B, C918, and (B) D78 cells as detected by RT-PCR. Abbreviations: mRNA, messenger RNA; RT-PCR, real-time polymerase chain reaction.

Article Snippet: Primary antibodies used for immunohistochemical evaluation included an antihuman polyclonal p53 antibody (1:500, clone CM1; Beijing Zhongshan Golden Bridge Biotechnology Co., Ltd.).

Techniques: Reverse Transcription Polymerase Chain Reaction, Real-time Polymerase Chain Reaction

Journal: OncoTargets and Therapy

Article Title: Evaluation of p53 gene expression and prognosis characteristics in uveal melanoma cases

doi: 10.2147/ott.s136785

Figure Lengend Snippet: Figure 2 Expression of p53 protein in MUM-2B, C918, and D78 cells as detected by Western blot.

Article Snippet: Primary antibodies used for immunohistochemical evaluation included an antihuman polyclonal p53 antibody (1:500, clone CM1; Beijing Zhongshan Golden Bridge Biotechnology Co., Ltd.).

Techniques: Expressing, Western Blot

Journal: OncoTargets and Therapy

Article Title: Evaluation of p53 gene expression and prognosis characteristics in uveal melanoma cases

doi: 10.2147/ott.s136785

Figure Lengend Snippet: Figure 4 The cell invasion ability was measured by a transwell assay at 48 hours after p53 overexpression in cells. Note: Magnification ×200.

Article Snippet: Primary antibodies used for immunohistochemical evaluation included an antihuman polyclonal p53 antibody (1:500, clone CM1; Beijing Zhongshan Golden Bridge Biotechnology Co., Ltd.).

Techniques: Transwell Assay, Over Expression

Journal: OncoTargets and Therapy

Article Title: Evaluation of p53 gene expression and prognosis characteristics in uveal melanoma cases

doi: 10.2147/ott.s136785

Figure Lengend Snippet: Figure 3 Expression of p53 protein in pathological tissues as detected by immunohistochemistry method (400×).

Article Snippet: Primary antibodies used for immunohistochemical evaluation included an antihuman polyclonal p53 antibody (1:500, clone CM1; Beijing Zhongshan Golden Bridge Biotechnology Co., Ltd.).

Techniques: Expressing, Immunohistochemistry

Journal: Cancer Immunology, Immunotherapy : CII

Article Title: Study on pathological factors affecting the sensitivity of neoadjuvant therapy in hypopharyngeal cancer

doi: 10.1007/s00262-025-03957-w

Figure Lengend Snippet: A. Differences in P53 expression between different therapeutic groups, ** p = 0.0017; B. Differences in P16 expression between different therapeutic groups, p = 0.0880; C. Differences in Ki67 expression between different therapeutic groups, ** p = 0.0005; D. Relationship between the combination of P53 and Ki67 expression levels and the efficacy. ** p < 0.01

Article Snippet: The incubation temperature and time of P16 protein antibody, Ki-67 protein antibody and P53 protein antibody were 37 °C for 40 min. Reagents were purchased from Beijing Zhongshan Jinqiao Company.

Techniques: Expressing

Journal: Cancer Immunology, Immunotherapy : CII

Article Title: Study on pathological factors affecting the sensitivity of neoadjuvant therapy in hypopharyngeal cancer

doi: 10.1007/s00262-025-03957-w

Figure Lengend Snippet: Relationship between the combination of P53 and Ki67 expression levels and the efficacy

Article Snippet: The incubation temperature and time of P16 protein antibody, Ki-67 protein antibody and P53 protein antibody were 37 °C for 40 min. Reagents were purchased from Beijing Zhongshan Jinqiao Company.

Techniques: Expressing

Journal: Cancer Immunology, Immunotherapy : CII

Article Title: Study on pathological factors affecting the sensitivity of neoadjuvant therapy in hypopharyngeal cancer

doi: 10.1007/s00262-025-03957-w

Figure Lengend Snippet: The immunohistochemical expression of Ki67 and P53 in different efficacy groups (100X). A.Ki67 < 60; B.Ki67 ≥ 60; C. P53 mutant; D.P53 wild type

Article Snippet: The incubation temperature and time of P16 protein antibody, Ki-67 protein antibody and P53 protein antibody were 37 °C for 40 min. Reagents were purchased from Beijing Zhongshan Jinqiao Company.

Techniques: Immunohistochemical staining, Expressing, Mutagenesis

Journal: Cancer Immunology, Immunotherapy : CII

Article Title: Study on pathological factors affecting the sensitivity of neoadjuvant therapy in hypopharyngeal cancer

doi: 10.1007/s00262-025-03957-w

Figure Lengend Snippet: Correlation analysis between pathological indicators and efficacy in different neoadjuvant therapies. A. Differences in therapeutic efficacy among patients with different expressions of P53, P16, and Ki67 in the neoadjuvant chemotherapy group; B. Differences in therapeutic efficacy among patients with different P53, P16, and Ki67 expression in the neoadjuvant targeted + chemotherapy group; C. Differences in therapeutic efficacy among patients with different expressions of P53, P16, and Ki67 in the neoadjuvant immunotherapy + chemotherapy group. * p < 0.05

Article Snippet: The incubation temperature and time of P16 protein antibody, Ki-67 protein antibody and P53 protein antibody were 37 °C for 40 min. Reagents were purchased from Beijing Zhongshan Jinqiao Company.

Techniques: Drug discovery, Expressing

Journal: Frontiers in Nutrition

Article Title: Sulforaphane attenuates aldose reductase-mediated platelet dysfunction in high glucose-stimulated human platelets via downregulation of the Src/ROS/p53 signaling pathway

doi: 10.3389/fnut.2025.1663245

Figure Lengend Snippet: Sulforaphane downregulates AR-mediated ROS/p53 signaling in HG-stimulated human platelets. (A–D) Washed human platelets were pre-incubated with SFN (5, 10, or 20 μM) or vehicle control for 40 min, followed by stimulation with NG or HG for additional 90 min. (A,B) Intraplatelet ROS levels were measured by flow cytometry. (C,D) Platelets were lysed and phosphorylation of p38α MAPK (C) and p53 (D) were determined by Western blotting. (E–J) Washed human platelets were pre-incubated with SFN (20 μM) with or without a ROS scavenger NAC (500 μM) (E–G) or ARI (10 μM) (H–J) for 40 min, followed by stimulation with NG or HG for additional 90 min. Intraplatelet ROS levels (E,H) , and phosphorylation of p38α MAPK (F,I) and p53 (G,J) were determined. Data were assessed by a one-way ANOVA followed by Dunnett’s t -test in (A–D) and by Tukey’s multiple comparisons test in (E–J) ( n = 3). * p < 0.05, ** p < 0.01 and *** p < 0.001 vs. the vehicle control; # p < 0.05 and ## p < 0.01; ns, not significant difference.

Article Snippet: Antibody against phospho-p53 was purchased from OriGene (MD, USA).

Techniques: Incubation, Control, Flow Cytometry, Phospho-proteomics, Western Blot

Journal: Frontiers in Nutrition

Article Title: Sulforaphane attenuates aldose reductase-mediated platelet dysfunction in high glucose-stimulated human platelets via downregulation of the Src/ROS/p53 signaling pathway

doi: 10.3389/fnut.2025.1663245

Figure Lengend Snippet: Sulforaphane attenuates ROS/p53 signaling through downregulating AR-mediated activation of Src family kinases in HG-stimulated human platelets. (A) Washed human platelets were pre-incubated with SFN (5, 10, or 20 μM) or vehicle control for 40 min, followed by stimulation with NG or HG for additional 90 min. Platelets were lysed and Src phosphorylation was determined by Western blotting. (B) Washed human platelets were pre-incubated with SFN (20 μM) with or without ARI (10 μM) for 40 min, followed by stimulation with NG or HG for additional 90 min. Src phosphorylation was determined. (C–G) Washed human platelets were pre-incubated with SFN (20 μM) with or without a Src inhibitor PP2 (20 μM) for 40 min, followed by stimulation with NG or HG for additional 90 min. Src phosphorylation (C) , intraplatelet ROS levels (D,E) , and phosphorylation of p38α MAPK (F) and p53 (G) were determined. Data were assessed by a one-way ANOVA followed by Dunnett’s t -test in (A) and by Tukey’s multiple comparisons test in (B–G) ( n = 3). * p < 0.05, ** p < 0.01 and *** p < 0.001 vs. the vehicle control; ns, not significant difference.

Article Snippet: Antibody against phospho-p53 was purchased from OriGene (MD, USA).

Techniques: Activation Assay, Incubation, Control, Phospho-proteomics, Western Blot

Journal: Frontiers in Nutrition

Article Title: Sulforaphane attenuates aldose reductase-mediated platelet dysfunction in high glucose-stimulated human platelets via downregulation of the Src/ROS/p53 signaling pathway

doi: 10.3389/fnut.2025.1663245

Figure Lengend Snippet: Sulforaphane attenuates AR-mediated platelet dysfunction mainly through downregulating Src/ROS/p53 signaling in HG-stimulated human platelets. Washed human platelets were pre-incubated with SFN (20 μM) with or without PP2 (20 μM) (A–D) , NAC (500 μM) (E–H) , or a p53 inhibitor PFT-μ (20 μM) (I–L) for 40 min, followed by stimulation with NG or HG for additional 90 min. Platelet Δψm dissipation (A,E,I) and PS exposure (B,F,J) were determined using flow cytometry. Platelet aggregation was stimulated by 1 μg/mL collagen (C,G,K) . Platelet surface expression of CD62P was analyzed by flow cytometry (D,H,L) . Data were assessed by a one-way ANOVA followed by Tukey’s multiple comparisons test ( n = 3). * p < 0.05, ** p < 0.01 and *** p < 0.001 vs. the vehicle control; # p < 0.05, ## p < 0.01, and ### p < 0.001; ns, not significant difference.

Article Snippet: Antibody against phospho-p53 was purchased from OriGene (MD, USA).

Techniques: Incubation, Flow Cytometry, Expressing, Control

Journal: Frontiers in Nutrition

Article Title: Sulforaphane attenuates aldose reductase-mediated platelet dysfunction in high glucose-stimulated human platelets via downregulation of the Src/ROS/p53 signaling pathway

doi: 10.3389/fnut.2025.1663245

Figure Lengend Snippet: Proposed mechanism of SFN in attenuating platelet dysfunction under HG conditions. SFN alleviates HG-induced platelet mitochondrial dysfunction, apoptosis, and hyperreactivity primarily through suppression of AR activity. This inhibition downregulates the Src/ROS/p53 signaling pathway, ultimately protecting against hyperglycemia-associated atherothrombosis by normalizing platelet function.

Article Snippet: Antibody against phospho-p53 was purchased from OriGene (MD, USA).

Techniques: Activity Assay, Inhibition